152 related articles for article (PubMed ID: 31217818)
1. An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype.
Guan Y; Shen Y; Xu Y; Li C; Wang J; Gu W; Lian P; Huang D; Cai S; Zhang Z; Zhu J
Therap Adv Gastroenterol; 2019; 12():1756284819852293. PubMed ID: 31217818
[TBL] [Abstract][Full Text] [Related]
2. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
Zhu J; Li X; Shen Y; Guan Y; Gu W; Lian P; Sheng W; Cai S; Zhang Z
Radiother Oncol; 2018 Oct; 129(1):143-148. PubMed ID: 29273261
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by
Zhu J; Liu A; Sun X; Liu L; Zhu Y; Zhang T; Jia J; Tan S; Wu J; Wang X; Zhou J; Yang J; Zhang C; Zhang H; Zhao Y; Cai G; Zhang W; Xia F; Wan J; Zhang H; Shen L; Cai S; Zhang Z
J Clin Oncol; 2020 Dec; 38(36):4231-4239. PubMed ID: 33119477
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial.
Wang J; Fan J; Li C; Yang L; Wan J; Zhang H; Zhang Z; Zhu J
Clin Colorectal Cancer; 2020 Jun; 19(2):e58-e69. PubMed ID: 32265117
[TBL] [Abstract][Full Text] [Related]
5. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration.
Jiang PC; Wang SW; Li C; Fan J; Zhu J
Int J Cancer; 2024 Apr; 154(8):1484-1491. PubMed ID: 38158593
[TBL] [Abstract][Full Text] [Related]
7. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
8. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group.
Fleischmann M; Diefenhardt M; Nicolas AM; Rödel F; Ghadimi M; Hofheinz RD; Greten FR; Rödel C; Fokas E;
Clin Transl Radiat Oncol; 2022 May; 34():99-106. PubMed ID: 35449546
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
Kimura K; Yamano T; Igeta M; Imada A; Jihyung S; Babaya A; Hamanaka M; Kobayashi M; Tsukamoto K; Noda M; Ikeda M; Tomita N
Cancer Sci; 2018 Dec; 109(12):3934-3942. PubMed ID: 30246377
[TBL] [Abstract][Full Text] [Related]
10. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010).
Hashimoto T; Tsukamoto S; Murofushi K; Ito Y; Hirano H; Tsukada Y; Sasaki K; Mizusawa J; Fukuda H; Takashima A; Kanemitsu Y
BJS Open; 2023 Nov; 7(6):. PubMed ID: 37931233
[TBL] [Abstract][Full Text] [Related]
12. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Gollins SW; Myint S; Susnerwala S; Haylock B; Wise M; Topham C; Samuel L; Swindell R; Morris J; Mason L; Levine E
Br J Cancer; 2009 Sep; 101(6):924-34. PubMed ID: 19690550
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
14. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
15. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
16. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
17. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Ngan SY; Michael M; Mackay J; McKendrick J; Leong T; Lim Joon D; Zalcberg JR
Br J Cancer; 2004 Sep; 91(6):1019-24. PubMed ID: 15305186
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
